On November 10, the Food and Drug Administration approved tremelimumab, or Imjudo, from AstraZeneca Pharmaceuticals in combination with durvalumab, or Imfinzi, from AstraZeneca Pharmaceuticals and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer, or NSCLC, with no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumor aberrations. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- FDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination Treatment
- Viatris wins court decision invalidating AstraZeneca’s Symbicort patent
- AstraZeneca (NASDAQ:AZN) Stock Rises on Upbeat Q3 Results, Guidance Lift
- AstraZeneca drops plans to submit COVID-19 vaccine to U.S. FDA, WSJ reports
- AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage